Brief: Zealand Pharma Keeps FY Guidance Unchanged

Zealand Pharma A/S

14/08/2025 06:10

Aug 14 (Reuters) - Zealand Pharma A/S ZELA.CO:

H1 OPERATING EXPENSES DKK -968 MILLION

H1 OPERATING RESULT DKK 8,128 MILLION

H1 REVENUE DKK 9,096 MILLION

OUTLOOK FY OPERATING EXPENSES DKK 2,000-2,500 MILLION

GUIDANCE UNCHANGED

SURVODUTIDE, GLUCAGON/GLP-1 RECEPTOR DUAL AGONIST DATA ARE EXPECTED IN FIRST HALF OF 2026

Source text: ID:nGNE5yr9Vb

Further company coverage: ZELA.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))